Sedation In ICU Setting Market Size, Share and Industry Analysis By Drug/Drug Class (Propofol, Benzodiazepams (Midazolam, etc.), Dexmedetomidine, Remifentanil), and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

                                          
We have updated Sedation In ICU Setting Market with respect to COVID-19 Business Impact.
Inquire before buying


This report focuses on the Sedation In ICU Setting market and value at the global level, regional level, and company level. From a global perspective, this report represents the overall Sedation In ICU Setting market size by analyzing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America.


Global Sedation In ICU Setting Market: Segment Analysis


The research report includes specific segments by region (country), by Company, by Type, and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2019 to 2029. An in-depth analysis of the segments assists in identifying the different factors that will aid market growth.


Global Sedation In ICU Setting Market: Regional Analysis


The research report includes a detailed study of regions of North America, Europe, Japan, China, Southeast Asia, India, Latin America, and South America. The report has been curated after observing and studying various factors that determine regional growth such as the economic, environmental, social, technological, and political status of the particular region. Researchers have studied the data of revenue, sales, and manufacturers of each mentioned region. This section analyses region-wise revenue and volume for the forecast period of 2019 to 2029.


Global Sedation In ICU Setting Market: Competitive Landscape


This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2019 to 2029.
List of Companies Profiled

  
Astra Zeneca
  
GlaxoSmithKline
  
Mylan N.V.
  
Fresenius Kabi
  
Teva Pharmaceutical Industries
  
B. Braun Medical
  
Aspen Holdings
  
Other prominent players

Report Coverage

Currently, Benzodiazepines such as Midazolam and Lorazepam considered to be the largest group of drug class holds significant market share in market for sedatives used in mechanically ventilated patients in the ICU settings. Dexmedetomidine is considered to be the fastest growing sedative used in mechanically ventilated ICU patients owing to higher efficiency and comparatively lower adverse effects compared to existing sedatives.

The report on sedation in ICU setting market provides qualitative and quantitative insights on the sedation in ICU setting industry trends and detailed analysis of market size & growth rate for all possible segments in the market. The sedation in ICU setting market segments include drug/drug class and by region.

In terms of durgs/drug class, the global market is categorized into propofol, benzodiazepines (midazolam, etc.), dexmedetomidine, remifentanil, and others. Geographically, the global market is segmented into four major regions, which are North America, Europe, Asia Pacific, and rest of the World. The regions are further categorized into countries.
Along with this, the report on global sedation in ICU setting market analysis comprises of the market dynamics and competitive landscape. Various key insights provided in the report are the guidelines for sedation in icu setting -for key countries, technological advancements, pipeline analysis, and advantages & disadvantages of various types of sedation in icu setting by drug class.

SEGMENTATION

By Drug/Drug Class

  
Propofol
  
Benzodiazepines (Midazolam, etc.)
  
Dexmedetomidine
  
Remifentanil
  
Others

By Geography

  
North America (USA and Canada)
  
Europe (UK, Germany, France, Italy, Spain, Sweden, Norway, Denmark, Finland, Benelux, Russia and Rest of
  
Europe)
  
Asia Pacific (Japan, China, India, South Korea, and Rest of Asia Pacific)
  
Rest of the World

Key Industry Developments

In September 2011, the European Commission has granted Dexdor (dexmedetomidine) from Orion, centralized approval covering 27 European Union countries for sedation of adult intensive care unit patients

In August 2014, Mylan, N.V. launched dexmedetomidine hydrochloride injection, a therapeutically equivalent version of Precedex

In June 2016, Aspen Holdings signed an agreement with AstraZeneca AB and AstraZeneca to gain exclusive rights to commercialize AstraZenecas global (excluding the USA) anesthetic portfolio